Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors-Reference-Cited by-同舟云学术

Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors

Published:2016-07 Issue: Volume:61 Page:44-51
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Fuerea Alina,Baciarello Giulia,Patrikidou Anna,Albigès Laurence,Massard Christophe,Di Palma Mario,Escudier Bernard,Fizazi Karim,Loriot Yohann

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference28 articles.

1. Cancer statistics, 2014;Siegel;CA Cancer J Clin,2014

2. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012;Ferlay;Eur J Cancer,2013

3. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel;Fitzpatrick;Eur J Cancer,2014

4. Prostate cancer: ESMO Consensus Conference Guidelines 2012;Horwich;Ann Oncol,2013

5. Molecular circuits of solid tumors: prognostic and predictive tools for bedside use;Ferté;Nat Rev Clin Oncol,2010

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial;European Urology;2024-09

2. Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients;European Journal of Nuclear Medicine and Molecular Imaging;2024-08-29

3. Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study;European Urology Oncology;2024-04

4. The prognostic value of Eastern Cooperative Oncology Group performance status on overall survival among patients with metastatic prostate cancer: a systematic review and meta-analysis;Frontiers in Oncology;2023-12-15

5. Multitask Learning of Longitudinal Circulating Biomarkers and Clinical Outcomes: Identification of Optimal Machine-Learning and Deep-Learning Models;2023-08-21